Business
Next Super Stocks on The Move: Tetra Bio-Pharma, ESE Entertainment, Red Light Holland, and Skylight Health. Innovation Leaders in E-Sports, Healthcare, Psychedelics, and Pharma Targeting Billion Dollar Markets.
Next Super Stocks on The Move: Tetra Bio-Pharma, ESE Entertainment, Red Light Holland, and Skylight Health. Innovation Leaders in E-Sports, Healthcare, Psychedelics, and Pharma Targeting Billion Dollar Markets..
About this update from Tetra Bio-pharma Inc.
[{"type":"text","content":"\n NEW YORK, April 29, 2021 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor “LiveChats” on social media streams. Over 170,000 investors have participated in Wall Street Reporter’s livestream events in the past 30 days. Tetra Bio-Pharma (OTC: TBPMF) (TSX: TBP) CEO, Dr. Guy Chamberland: “Expecting to Launch 3 New Cannabinoid-Derived Drugs in 2022 - Addressing $200 Billion Market Opportunities” In a recent presentation at Wall Street Reporter’s NEXT SUPER STOCK livestream, Tetra BioPharma (OTC: TBPMF) CEO, Dr. Guy Chamberland shared TBPMF’s advanced pipeline of cannabinoid derived drugs targeting $200 billion addressable market opportunities including pain, inflammation, oncology, and sepsis. TBPMF boasts one of the most advanced pipelines of Cannabinoid-derived medicines, supported by the urgent need for non-opioid alternatives to treat pain and inflammation. Significantly, TBPMF’s portfolio of IP and patents is spearheaded by a team experienced at bringing new drugs to market. TBPMF now has 3 drugs in the advanced clinical stages, which it expects to bring to market in 2022: Quixleef targeting pain management, a $58 billion market opportunity, ARDS-003 immunomodulator which is a $132 billion market opportunity, and PPP-003 for ophthalmic inflammation indication - a $31 billion market. Compelling for investors, TBMPF has multiple near-term catalysts in place, and with a current valuation of about $50 million, TBPMF is trading at a just a small fraction of it’s peer group in the biotech space, with similar pipelines. Watch Tetra Bio-Pharma (OTC: TBPMF) Next Super Stock 4/21/21 video: https://bit.ly/2QzBElc Red Light Holland (OTC: TRUFF) (CSE: TRIP) CEO Todd Shapiro: ”Psychedelics is Next Billion Dollar Market Opportunity” In a recent presentation on Wall Street Reporter’s NEXT SUPER STOCK livestream, Red Light Holland (OTC: TRUFF) (CSE: TRIP), CEO Todd Shapiro updated investors on the TRUFF’s latest market expansion and success in the psychedelics sector, and major new growth opportunities in coming months. TRUFF produces and sells recreational gr...